Related Experiment Video
Updated: May 4, 2026

Chondrogenic Differentiation Induction of Adipose-derived Stem Cells by Centrifugal Gravity
Published on: February 24, 2017
Down regulation of differentiated embryo-chondrocyte expressed gene 1 is related to the decrease of osteogenic
Hu Jinhua, Mao Zhao, Shang Wei
1Department of pharmacology, Nanjing medicine University, Nanjing, 210029, China. jianyang@njmu.edu.cn.
Abstract:
Differentiated embryo-chondrocyte expressed gene 1 (DEC1) is associated with chondrogenesis, neurogenesis, immune response, biological rhythm, lipogenesis, cell differentiation and carcinogenesis. However, there is little information about its contribution to osteoblast osteogenesis. In the present study, we report that DEC1 expression increases along with the degree of mineralization, which parallells with the increase of osteogenesis induction time in SaoS-2 cells. Dexamethasone (DEX) decreases the osteogenesis capacity such as alkaline phosphatase (ALP) activity and mineralization along with decreasing the DEC1 expression. On the contrary, 17β-estradiol (E2) increases the osteogenesis along with increasing the DEC1 expression. Moreover, the overexpression of DEC1 alone increases the ALP activity and mineralization synchronously, and it not only partially reverses the decrease of ALP activity induced by DEX, but almost abolishes the decrease of mineralized nodules induced by DEX. On the other hand, the DEC1 expression decreases in tibia bone marrow side of ovariectomy mice compared with that in sham-operated mice, and E2 treatment ameliorates the decrease of DEC1 expression induced by bilateral ovariectomy and prevents osteoporosis in ovariectomized mice . Taken together, downregulation of DEC1 expression is related to the decrease of osteogenic capacity. The findings provide a novel target for the therapy of osteoporosis.
Insights
Differentiated embryo-chondrocyte expressed gene 1 (DEC1) promotes osteoblast differentiation and bone mineralization. Lowering DEC1 expression reduces osteogenic capacity, suggesting DEC1 as a therapeutic target for osteoporosis.
Area of Science:
- Biochemistry
- Cell Biology
- Endocrinology
Background:
- Differentiated embryo-chondrocyte expressed gene 1 (DEC1) is implicated in various cellular processes.
- Its role in osteoblast osteogenesis remains largely uncharacterized.
Purpose of the Study:
- To investigate the role of DEC1 in osteoblast differentiation and its potential link to osteoporosis.
Main Methods:
- Utilized SaoS-2 cells to examine DEC1 expression during osteogenesis induction.
- Investigated the effects of dexamethasone (DEX) and 17β-estradiol (E2) on DEC1 expression and osteogenic markers.
- Assessed DEC1's impact on osteogenesis via overexpression studies.
- Examined DEC1 expression in ovariectomized mice models.
Main Results:
- DEC1 expression positively correlates with osteogenesis and mineralization in SaoS-2 cells.
- DEX treatment decreased osteogenic capacity and DEC1 expression, while E2 increased both.
- DEC1 overexpression enhanced alkaline phosphatase (ALP) activity and mineralization, partially reversing DEX-induced decreases.
- DEC1 expression was reduced in ovariectomized mice, and E2 treatment normalized DEC1 levels and prevented bone loss.
Conclusions:
- Downregulation of DEC1 is associated with decreased osteogenic capacity.
- DEC1 plays a crucial role in osteoblast differentiation and bone health.
- DEC1 represents a potential therapeutic target for osteoporosis treatment.
Related Concept Videos
Master Transcription Regulators
Growth of Cartilage and Bone Tissue
Bone Formation by Endochondral Ossification
Regulation of Expression at Multiple Steps
Regulation of Angiogenesis and Blood Supply
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

